2015
Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer
Shen Y, Katsaros D, Loo LW, Hernandez BY, Chong C, Canuto EM, Biglia N, Lu L, Risch H, Chu WM, Yu H. Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer. Oncotarget 2015, 6: 8579-8592. PMID: 25865225, PMCID: PMC4496168, DOI: 10.18632/oncotarget.3287.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Agents, HormonalBreast NeoplasmsCarcinomaCell DivisionCell Line, TumorCell MovementChemotherapy, AdjuvantDisease-Free SurvivalFemaleGene ExpressionGenes, Tumor SuppressorGenetic VectorsHumansMiddle AgedNeoplasm GradingNeoplasm StagingPrognosisRecurrenceRiskRNARNA, Long NoncodingRNA, NeoplasmTissue Array AnalysisTreatment OutcomeYoung AdultConceptsLINC00472 expressionBreast cancerPredictive valueBreast tumorsLow expressionBreast cancer cell proliferationFavorable molecular subtypesNormal-like tumorsFavorable disease outcomeAggressive breast tumorsRisk of relapseCell proliferationCancer cell proliferationBreast cancer cellsBreast tumor samplesAdjuvant chemoHormonal therapyLuminal AClinical managementDisease outcomeGene Expression Omnibus databaseMolecular subtypesLong non-coding RNALINC00472Tumor samples
2011
Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome
Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D, Yu H. Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome. Breast Cancer Research 2011, 13: r56. PMID: 21645396, PMCID: PMC3218945, DOI: 10.1186/bcr2893.Peer-Reviewed Original ResearchConceptsEndocrine therapyDisease outcomeAdjuvant treatmentTelomerase expressionBetter survival outcomesDisease-free survivalHormone receptor statusBreast cancer patientsRisk of deathTelomere lengthHigh telomeraseCause-specific mortalityBreast cancer prognosisBreast cancer cellsCancer cell resistanceHigh telomerase expressionOverall survivalPatient ageDisease recurrenceReceptor statusHistological typeAggressive diseaseSurvival outcomesDisease stageCancer patients